No­var­tis’ $2B can­cer drug spurs ‘ground­break­ing’ PhI­II da­ta for prostate can­cer

Con­tin­u­ing a streak of up­beat an­nounce­ments on its ra­di­oli­gand port­fo­lio, No­var­tis says that their Phase III study of 177Lu-PS­MA-617 hit both co-pri­ma­ry end­points on over­all sur­vival and ra­di­ograph­ic pro­gres­sion-free sur­vival for prostate can­cer pa­tients — set­ting up a like­ly ap­proval some an­a­lysts be­lieve would be worth more than a bil­lion dol­lars a year in peak sales.

In­ves­ti­ga­tors tried the treat­ment on pro­gres­sive PS­MA-pos­i­tive metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer pa­tients, com­par­ing it against stan­dard of care. We don’t have the ex­act da­ta, but No­var­tis typ­i­cal­ly holds back spe­cif­ic re­sults for the can­cer con­fer­ences.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER